Verschiedene Medikamente in Tabletten- und Kapselform. (Symbolbild)
Mittwoch, 15.02.2017 18:47 von | Aufrufe: 567

Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600

Verschiedene Medikamente in Tabletten- und Kapselform. (Symbolbild) © pixabay.com/CC0 https://pixabay.com

PR Newswire

NEW YORK, Feb. 15, 2017 /PRNewswire/ -- Effective with this press release, S&P Dow Jones Indices will now reference index changes using an "effective at the open" date rather than an "after the close of trading" date which is current practice.

Progenics Pharmaceuticals Inc. (NASD: PGNX) will replace Calamos Asset Management Inc. (NASD: CLMS) in the S&P SmallCap 600 effective at the open of Tuesday, February 21. Calamos Asset Management is being taken private in a transaction expected to be completed soon pending final conditions.

Shutterfly Inc. (NASD: SFLY) will replace Vascular Solutions Inc. (NASD: VASC) in the S&P SmallCap 600 effective at the open of Tuesday, February 21. S&P MidCap 400 constituent Teleflex Inc. (NYSE:TFX) is acquiring Vascular Solutions in a transaction expected to be completed soon pending final conditions.

Progenics Pharmaceuticals develops medicines for oncology. Headquartered in Tarrytown, NY, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Biotechnology Sub-Industry index.

Shutterfly manufactures and retails personalized products and services. Headquartered in Redwood City, CA, the company will be added to the S&P SmallCap 600 GICS Internet & Direct Marketing Retail Sub-Industry index.

Following is a summary of the changes:

S&P SMALLCAP 600 INDEX – FEBRUARY 21, 2017


ARIVA.DE Börsen-Geflüster

Kurse

Calamos Asset Management Chart
Progenics Pharmaceuticals Chart
386,10
-0,32%
S&P Global Inc Realtime-Chart
-  
0,00%
Shutterfly Chart
193,00
0,00%
Teleflex Realtime-Chart
Vascular Solutions Chart

COMPANY

GICS ECONOMIC SECTOR

GICS SUB-INDUSTRY

ADDED

Progenics

Health Care

Biotechnology


Shutterfly

Consumer Discretionary

Internet & Direct
Marketing Retail

DELETED

Calamos Asset
Management

Financials

Asset Management &
Custody Banks


Vascular
Solutions

Health Care

Health Care Supplies

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than based on any other provider in the world. With over 1,000,000 indices and more than 120 years of experience constructing innovative and transparent solutions, S&P Dow Jones Indices defines the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

Soogyung Jordan
Global Head of Communications
New York, USA
(+1) 212 438 2297
soogyung.jordan@spdji.com

David Blitzer
Managing Director and Chairman of the Index Committee
New York, USA
(+1) 212 438 3907
david.blitzer@spglobal.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/progenics-pharmaceuticals-and-shutterfly-to-join-sp-smallcap-600-300408455.html

SOURCE S&P Dow Jones Indices

Werbung

Mehr Nachrichten zur Progenics Pharmaceuticals Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.